Document is current
Any future updates will be listed below
-
Authors
Li, Linlin
Wang, Jiarou
Wang, Guochang
Wang, Rongxi
Jin, Wenbin
Zang, Jie
Sui, Huimin
Jia, Chenhao
Jiang, Yuanyuan
Hong, Haiyan
Zhu, Lin
Alexoff, David
Ploessl, Karl
Kung, Hank F. https://orcid.org/0000-0003-3254-8049
Zhu, Zhaohui
-
Funding
Funding for this research was provided by:
the National High Level Hospital Clinical Research Funding (2022-PUMCH-C-004)
the Fundamental Research Funds for the Central Universities (3332022110)
Chinese Academy of Medical Science Innovation Fund for Medical Sciences (2021-I2M-1-016, 2022-I2M-C&T-A-008, 2022-I2M-2-002)
the National Natural Science Foundation of China (82272046, 22176016)
- License Information
-
More Information
Article History
Received: 9 January 2024
Accepted: 15 April 2024
First Online: 25 April 2024
Declarations
:
: This study was approved by the Institute Review Board of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (no. ZS-3567), and registered at clinicaltrials.gov (NCT05603559).
: David Alexoff, Karl Ploessl and Hank F. Kung are employees of Five Eleven Pharma Inc. which holds the patent rights for [<sup>177</sup>Lu]Lu-P17-087 and [<sup>177</sup>Lu]Lu-P17-088 and related technology. Dr. Hank F. Kung is also the Founder and Chairman of the board at Five Eleven Pharma Inc. Other authors declare no other conflict of interests.
